ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 339 filers reported holding ACCELERON PHARMA INC in Q3 2021. The put-call ratio across all filers is 0.38 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $19,531,000 | +198.4% | 113,485 | +117.6% | 0.00% | +100.0% |
| Q2 2021 | $6,545,000 | -17.8% | 52,156 | -11.2% | 0.00% | 0.0% |
| Q1 2021 | $7,959,000 | +32.4% | 58,702 | +24.9% | 0.00% | 0.0% |
| Q4 2020 | $6,011,000 | -69.7% | 46,983 | -73.2% | 0.00% | -66.7% |
| Q3 2020 | $19,811,000 | +138.8% | 175,143 | +101.1% | 0.00% | +50.0% |
| Q2 2020 | $8,296,000 | +8.4% | 87,088 | +2.3% | 0.00% | 0.0% |
| Q1 2020 | $7,652,000 | +68.1% | 85,144 | -0.8% | 0.00% | +100.0% |
| Q4 2019 | $4,552,000 | +62.2% | 85,846 | +20.9% | 0.00% | 0.0% |
| Q3 2019 | $2,806,000 | +1.4% | 70,991 | +5.0% | 0.00% | 0.0% |
| Q2 2019 | $2,767,000 | -20.0% | 67,638 | -9.0% | 0.00% | 0.0% |
| Q1 2019 | $3,460,000 | +98.1% | 74,287 | +85.3% | 0.00% | – |
| Q4 2018 | $1,747,000 | -23.8% | 40,092 | +0.1% | 0.00% | – |
| Q3 2018 | $2,293,000 | -7.6% | 40,056 | -21.7% | 0.00% | -100.0% |
| Q2 2018 | $2,482,000 | -30.0% | 51,125 | -43.6% | 0.00% | 0.0% |
| Q1 2018 | $3,544,000 | -12.4% | 90,642 | -4.9% | 0.00% | 0.0% |
| Q4 2017 | $4,045,000 | +23.0% | 95,299 | +3.7% | 0.00% | 0.0% |
| Q3 2017 | $3,289,000 | -0.6% | 91,900 | -26.5% | 0.00% | 0.0% |
| Q1 2017 | $3,309,000 | -84.4% | 124,975 | -84.9% | 0.00% | -80.0% |
| Q4 2016 | $21,150,000 | -27.1% | 828,811 | +3.4% | 0.01% | -28.6% |
| Q3 2016 | $29,015,000 | +6.8% | 801,745 | +0.3% | 0.01% | 0.0% |
| Q2 2016 | $27,173,000 | +29.7% | 799,699 | +0.7% | 0.01% | +40.0% |
| Q1 2016 | $20,949,000 | -48.8% | 793,834 | -5.4% | 0.01% | -50.0% |
| Q4 2015 | $40,898,000 | +141.3% | 838,760 | +23.2% | 0.01% | +100.0% |
| Q3 2015 | $16,951,000 | -22.0% | 680,737 | -0.9% | 0.01% | 0.0% |
| Q2 2015 | $21,739,000 | -19.4% | 687,071 | -3.0% | 0.01% | -16.7% |
| Q1 2015 | $26,955,000 | +3.9% | 708,240 | +6.4% | 0.01% | 0.0% |
| Q4 2014 | $25,931,000 | +60.3% | 665,547 | +24.4% | 0.01% | +50.0% |
| Q3 2014 | $16,175,000 | -0.5% | 534,884 | +11.8% | 0.00% | 0.0% |
| Q2 2014 | $16,249,000 | -6.9% | 478,306 | -5.5% | 0.00% | -20.0% |
| Q1 2014 | $17,456,000 | -42.5% | 505,954 | -34.0% | 0.01% | -44.4% |
| Q4 2013 | $30,337,000 | – | 766,080 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |